ClinicalTrials.gg
CompletedNCT01860976ASTRAEAUpdated Apr 5, 2022Results posted

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

A Phase 3 interventional study of Abatacept and Placebo in Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Completed at 82 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-05.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
489
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.

Started
2013
the only one that year
Phase 3
4 of 12
1 open now
Registered
2nd of 12
by date

Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is the only one that started in 2013, is one of 4 in phase 3, and was the 2nd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to compare subcutaneous Abatacept to placebo in the treatment of psoriatic arthritis

Read the detailed description

ASTRAEA=Active PSoriaTic ARthritis RAndomizEd TriAl

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Subjects at least 18 years of age who have a diagnosis of PsA by Classification Criteria for Psoriatic Arthritis (CASPAR)
  • Subjects have active PsA as shown by a minimum of ≥3 swollen joints and ≥3 tender joints (66/68 joint counts) at screening and randomization/Day 1 (prior to study drug administration). At least one of the swollen joints must be in the digit of the hand or foot
  • Subjects with at least one confirmed ≥2 cm target lesion of plaque psoriasis in a region of the body that can be evaluated excluding the axilla, genitals, groin, palms, and soles
  • Subjects must have had an inadequate response or intolerance to at least one non-biologic disease-modifying anti-rheumatic drug (DMARD)
  • Subjects may have been exposed to TNFi therapy. Subjects may have discontinued for any reason (inadequate response, intolerance or other)
  • Subjects may enroll on certain concomitant non-biologic DMARDs (Methotrexate, Leflunomide, Sulfasalazine, or Hydroxychloroquine) provided the medication has been used for at least 3 months with a stable dose for at least 28 days prior to randomization (Day 1)
  • If using oral (≤10 mg mg/day Prednisone equivalent), dose must be stable ≥14 days prior to randomization (Day 1)
  • Subjects may enroll on systemic retinoids (eg: Acitretin) provided the medication has been used for at least 3 months with a stable dose for at least 28 days prior to randomization (Day 1)

Exclusion criteria

Exclusion Criteria:

  • Subjects with guttate, pustular, or erythrodermic psoriasis
  • Subjects who have had prior exposure to Abatacept (CTLA 4Ig) or other CTLA4 therapies
  • Subjects who have been exposed to any drug within 4 weeks or 5 half lives, whichever is longer
  • Female subjects who had a breast cancer screening study that is suspicious for , and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations
  • Subjects with a history of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection). Existing non-melanoma skin cell cancers must be removed prior to dosing. Subjects with carcinoma in situ, treated with definitive surgical intervention prior to study enrollment are allowed
  • Subjects with any bacterial infection within the last 60 days prior to screening (enrollment), unless treated and resolved with antibiotics, or any chronic bacterial infection (such as chronic pyelonephritis, osteomyelitis and bronchiectasis)
  • Subjects at risk for tuberculosis (TB). Specifically, subjects with:

    • Current clinical, radiographic or laboratory evidence of active TB
    • A history of active TB within the last 3 years even if it was treated
    • A history of active TB greater than 3 years ago unless there is documentation that the prior anti-TB treatment was appropriate in duration and type
    • Latent TB which was not successfully treated
    • Subjects with a positive TB screening test indicative of latent TB will not be eligible for the study unless they have no evidence of current TB on chest x-ray at screening and they are actively being treated for TB with isoniazid (INH) or other therapy for latent TB given according to local health authority guidelines (eg: Center for Disease Control). Treatment must have been given for at least 4 weeks prior to randomization (Day 1). These subjects should complete treatment according to local health authority guidelines
  • Subjects with herpes zoster that resolved less than 2 months prior to enrollment
  • Subjects with evidence (as measured by the investigator) of active or latent bacterial, active viral, or serious latent viral infections at the time of enrollment, including subjects with evidence of Immunodeficiency Virus () infection
  • Subjects who are not currently treated with a non-biologic DMARD and have clinical or radiographic evidence of arthritis mutilans (eg: digital telescoping or "pencil-in-cup" radiographic changes)
  • Subjects who have failed more than 2 TNFi due to inefficacy defined as inadequate response after 3 months treatment at a therapeutic dose
  • Subjects who have received TNFi therapy within 4 weeks for etanercept or within 8 weeks for adalimumab, certolizumab, infliximab, or golimumab
  • Subjects who have received prior use of apremilast within 4 weeks, ustekinumab within 20 weeks or briakinumab within 8 weeks
  • Subjects who have discontinued a non-biologic DMARD or systemic retinoid within four weeks or five half-lives, whichever is longer, prior to randomization (Day 1)
  • Use of any of the following within 28 days or five half lives whichever is longer prior to randomization (Day 1): Cyclosporine A, oral Tacrolimus, Mycophenolate Mofetil (MMF), Hydroxyurea, Fumaric Acid Esters, Paclitaxel, 6-Thioguanine, 6-Mercatopurine, or Tofacitinib
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
489 participants (actual)

Study arms

  • Experimental
    Abatacept

    Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension

    Drug: Abatacept

  • Placebo comparator
    Placebo

    Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind

    Drug: Placebo

Interventions

  • Also known as: Orencia

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Proportion of ACR 20 Responders at Day 169

    The American College of Rheumatology (ACR) 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

    Time frame: Day 169

Secondary outcomes

  1. Proportion of Health Assessment Questionnaire (HAQ) Responders at Day 169

    Participants were considered responders if their HAQ score decreased at least 0.35 from baseline. The number of HAQ responders was divided by the number of treated participants and expressed as a percentage. Scoring conventions are based on the Standard Disability Index of HAQ/HAQ-DI using the 20 response items. For each of the 8 disability categories there is an "aids/devices" companion variable that is used to record the type of assistance, if any, a participant uses for his/her usual activities. If either "aids/devices" and/or "assistance from another person" are checked for a disability category, the score for this category is set to "2" (much difficulty), if the original score was "0" (no difficulty) or "1" (some difficulty). The HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

    Time frame: Baseline to Day 169

  2. Proportion of ACR 20 Responders at Day 169 in the TNFi-naïve Subpopulation

    The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-naive participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

    Time frame: Day 169

  3. Proportion of ACR 20 Responders at Day 169 in the TNFi-exposed Subpopulation

    The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-exposed participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

    Time frame: Day 169

  4. Proportion of Non-progressors in Total PsA-modified SHS at Day 169

    The number of radiographic non-progressors in total PsA-Modified Sharp van der Heijde score (SHS) at Day 169 was divided by the number of treated participants and expressed as a percentage. Non-progression was defined as a change from baseline in total PsA modified SHS ≤0. Early escape participants, and participants with missing data at day 169 were imputed as non-progressors.

    Time frame: Baseline to Day 169

  5. Proportion of Participants Achieving a PASI 50 at Day 169 in Participants With Baseline BSA >= 3%

    The number of participants who achieved at least 50% improvement from baseline in Psoriasis Area and Severity Index Arthritis (PASI 50) at Day 169 was divided by the number of treated participants with BSA \>= 3% and expressed as a percentage. Only participants with \>= 3% body surface area (BSA) of psoriatic skin involvement at randomization were included in this analysis.

    Time frame: Baseline to Day 169

  6. Proportions of ACR 50 and ACR 70 Responders at Day 169

    The ACR 50 and ACR 70 definition of improvement is a 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 50% or 70% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 50 and ACR 70 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

    Time frame: Day 169

  7. Mean Change From Baseline in SF-36 Physical and Mental Components at Day 169

    Adjusted mean change in scores on the Short Form 36 physical and mental function assessment (SF-36) from baseline were analyzed from the physical component summary (PCS) mental component summary (MCS). The SF-36 is a participant questionnaire assessing 8 domains of health status: physical functioning, pain, vitality, social functioning, psychological functioning, general health perception, and role limitations due to physical and emotional problems. The instrument can be divided into two summary scores, physical and mental component score. The scores range from 0 to 100, with a higher score indicating better quality of life. The two summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales.

    Time frame: Baseline to Day 169

  8. Proportion of Participants With at Least One Positive Immunogenicity Response up to Day 169 Relative to Baseline

    Blood samples were collected at Days 1, 85 and 169 and assayed for the presence of abatacept-specific antibodies. The number of participants with at least one positive immunogenicity response was divided by the number of treated participants and expressed as a percentage.

    Time frame: Baseline to Day 169

  9. Proportion of Participants With AEs at Day 169

    Proportion of participants with AEs at Day 169

    Time frame: Day 169

  10. Proportion of Participants With SAEs at Day 169

    Proportion of participants with SAEs at Day 169

    Time frame: Day 169

  11. Proportion of Participants With AEs Leading to Discontinuation at Day 169

    Proportion of participants with AEs leading to discontinuation at Day 169

    Time frame: Day 169

  12. Proportion of Participant Deaths at Day 169

    Proportion of participant deaths at Day 169

    Time frame: Day 169

  13. Proportion of Participants With Marked Laboratory Abnormalities at Day 169

    Proportion of participants with marked laboratory abnormalities at Day 169

    Time frame: Day 169

07

Results

Posted Aug 2, 2017

Participant flow

Blinded Treatment
Participant flow — Blinded Treatment
MilestoneAbataceptPlacebo
Started213211
Completed12598
Not completed88113
Withdrew: Adverse event13
Withdrew: Lack of efficacy512
Withdrew: Subject request to discontinue treatment23
Withdrew: Withdrawal by subject35
Withdrew: Subject no longer met criteria10
Withdrew: Entered open-label in error01
Withdrew: Early escape: transitioned to ol period7689
Open-Label
Participant flow — Open-Label
MilestoneAbataceptPlacebo
Started197185
Completed169166
Not completed2819
Withdrew: Adverse event24
Withdrew: Lack of efficacy168
Withdrew: Lost to follow-up12
Withdrew: Subject request discontinue treatment43
Withdrew: Withdrawal by subject41
Withdrew: Other reasons11
Long Term Extension
Participant flow — Long Term Extension
MilestoneAbataceptPlacebo
Started1060
Completed810
Not completed250
Withdrew: Adverse event40
Withdrew: Lack of efficacy20
Withdrew: Subject request to discontinue treatment100
Withdrew: Lost to follow-up20
Withdrew: Subject withdrew consent70

Outcome measures

PrimaryProportion of ACR 20 Responders at Day 169

The American College of Rheumatology (ACR) 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportion of ACR 20 Responders at Day 169
Percentage of participantsAbataceptPlacebo
Proportion of ACR 20 Responders at Day 16939.4 (32.9 to 46.0)22.3 (16.7 to 27.9)
Statistical analysis
  • Abatacept vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Estimate of difference: 17.2 · 95% CI 8.7 to 25.6
SecondaryProportion of Health Assessment Questionnaire (HAQ) Responders at Day 169

Participants were considered responders if their HAQ score decreased at least 0.35 from baseline. The number of HAQ responders was divided by the number of treated participants and expressed as a percentage. Scoring conventions are based on the Standard Disability Index of HAQ/HAQ-DI using the 20 response items. For each of the 8 disability categories there is an "aids/devices" companion variable that is used to record the type of assistance, if any, a participant uses for his/her usual activities. If either "aids/devices" and/or "assistance from another person" are checked for a disability category, the score for this category is set to "2" (much difficulty), if the original score was "0" (no difficulty) or "1" (some difficulty). The HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

Time frame:
Baseline to Day 169
Reported as:
Number · percentage of participants
Proportion of Health Assessment Questionnaire (HAQ) Responders at Day 169
percentage of participantsAbataceptPlacebo
Proportion of Health Assessment Questionnaire (HAQ) Responders at Day 16931.0 (24.8 to 37.2)23.7 (18.0 to 29.4)
SecondaryProportion of ACR 20 Responders at Day 169 in the TNFi-naïve Subpopulation

The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-naive participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportion of ACR 20 Responders at Day 169 in the TNFi-naïve Subpopulation
Percentage of participantsAbataceptPlacebo
Proportion of ACR 20 Responders at Day 169 in the TNFi-naïve Subpopulation44.0 (33.4 to 54.7)22.2 (13.2 to 31.3)
SecondaryProportion of ACR 20 Responders at Day 169 in the TNFi-exposed Subpopulation

The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-exposed participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportion of ACR 20 Responders at Day 169 in the TNFi-exposed Subpopulation
Percentage of participantsAbataceptPlacebo
Proportion of ACR 20 Responders at Day 169 in the TNFi-exposed Subpopulation36.4 (28.1 to 44.7)22.3 (15.2 to 29.5)
SecondaryProportion of Non-progressors in Total PsA-modified SHS at Day 169

The number of radiographic non-progressors in total PsA-Modified Sharp van der Heijde score (SHS) at Day 169 was divided by the number of treated participants and expressed as a percentage. Non-progression was defined as a change from baseline in total PsA modified SHS ≤0. Early escape participants, and participants with missing data at day 169 were imputed as non-progressors.

Time frame:
Baseline to Day 169
Reported as:
Number · Percentage of participants
Proportion of Non-progressors in Total PsA-modified SHS at Day 169
Percentage of participantsAbataceptPlacebo
Proportion of Non-progressors in Total PsA-modified SHS at Day 16942.7 (36.1 to 49.4)32.7 (26.4 to 39.0)
SecondaryProportion of Participants Achieving a PASI 50 at Day 169 in Participants With Baseline BSA >= 3%

The number of participants who achieved at least 50% improvement from baseline in Psoriasis Area and Severity Index Arthritis (PASI 50) at Day 169 was divided by the number of treated participants with BSA \>= 3% and expressed as a percentage. Only participants with \>= 3% body surface area (BSA) of psoriatic skin involvement at randomization were included in this analysis.

Time frame:
Baseline to Day 169
Reported as:
Number · Percentage of participants
Proportion of Participants Achieving a PASI 50 at Day 169 in Participants With Baseline BSA >= 3%
Percentage of participantsAbataceptPlacebo
Proportion of Participants Achieving a PASI 50 at Day 169 in Participants With Baseline BSA >= 3%26.7 (19.5 to 33.9)19.6 (13.2 to 26.0)
SecondaryProportions of ACR 50 and ACR 70 Responders at Day 169

The ACR 50 and ACR 70 definition of improvement is a 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 50% or 70% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 50 and ACR 70 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportions of ACR 50 and ACR 70 Responders at Day 169
Percentage of participantsAbataceptPlacebo
ACR 5019.2 (14.0 to 24.5)12.3 (7.9 to 16.8)
ACR 7010.3 (6.2 to 14.4)6.6 (3.3 to 10.0)
SecondaryMean Change From Baseline in SF-36 Physical and Mental Components at Day 169

Adjusted mean change in scores on the Short Form 36 physical and mental function assessment (SF-36) from baseline were analyzed from the physical component summary (PCS) mental component summary (MCS). The SF-36 is a participant questionnaire assessing 8 domains of health status: physical functioning, pain, vitality, social functioning, psychological functioning, general health perception, and role limitations due to physical and emotional problems. The instrument can be divided into two summary scores, physical and mental component score. The scores range from 0 to 100, with a higher score indicating better quality of life. The two summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales.

Time frame:
Baseline to Day 169
Reported as:
Mean · SF-36 points
Mean Change From Baseline in SF-36 Physical and Mental Components at Day 169
SF-36 pointsAbataceptPlacebo
PCS5.11 ± 0.6373.69 ± 0.707
MCS2.56 ± 0.8262.62 ± 0.924
SecondaryProportion of Participants With at Least One Positive Immunogenicity Response up to Day 169 Relative to Baseline

Blood samples were collected at Days 1, 85 and 169 and assayed for the presence of abatacept-specific antibodies. The number of participants with at least one positive immunogenicity response was divided by the number of treated participants and expressed as a percentage.

Time frame:
Baseline to Day 169
Reported as:
Number · Percentage of participants
Proportion of Participants With at Least One Positive Immunogenicity Response up to Day 169 Relative to Baseline
Percentage of participantsAbataceptPlacebo
Proportion of Participants With at Least One Positive Immunogenicity Response up to Day 169 Relative to Baseline3.98.6
SecondaryProportion of Participants With AEs at Day 169

Proportion of participants with AEs at Day 169

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportion of Participants With AEs at Day 169
Percentage of participantsAbataceptPlacebo
Proportion of Participants With AEs at Day 16954.553.1
SecondaryProportion of Participants With SAEs at Day 169

Proportion of participants with SAEs at Day 169

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportion of Participants With SAEs at Day 169
Percentage of participantsAbataceptPlacebo
Proportion of Participants With SAEs at Day 1692.84.3
SecondaryProportion of Participants With AEs Leading to Discontinuation at Day 169

Proportion of participants with AEs leading to discontinuation at Day 169

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportion of Participants With AEs Leading to Discontinuation at Day 169
Percentage of participantsAbataceptPlacebo
Proportion of Participants With AEs Leading to Discontinuation at Day 1691.41.9
SecondaryProportion of Participant Deaths at Day 169

Proportion of participant deaths at Day 169

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportion of Participant Deaths at Day 169
Percentage of participantsAbataceptPlacebo
Proportion of Participant Deaths at Day 16900
SecondaryProportion of Participants With Marked Laboratory Abnormalities at Day 169

Proportion of participants with marked laboratory abnormalities at Day 169

Time frame:
Day 169
Reported as:
Number · Percentage of participants
Proportion of Participants With Marked Laboratory Abnormalities at Day 169
Percentage of participantsAbataceptPlacebo
Proportion of Participants With Marked Laboratory Abnormalities at Day 1693.25.4

Adverse events

Collected over Up to 56 days post last dose in the short-term period or the first dose in the open-label period, whichever occurs first. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABATACEPT DURING DOUBLE-BLIND PERIOD0/213 (0%)6/213 (2.8%)39/213 (18.3%)
PLACEBO DURING DOUBLE-BLIND PERIOD0/211 (0%)9/211 (4.3%)43/211 (20.4%)
ABATACEPT DURING OPEN-LABEL PERIOD0/382 (0%)29/382 (7.6%)92/382 (24.1%)
ABATACEPT DURING OPEN-LABEL EXTENSION PERIOD0/322 (0%)20/322 (6.2%)103/322 (32%)
ABATACEPT DURING LONG-TERM EXTENSION PERIOD0/106 (0%)17/106 (16%)56/106 (52.8%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventABATACEPT DURING DOUBLE-BLIND PERIODPLACEBO DURING DOUBLE-BLIND PERIODABATACEPT DURING OPEN-LABEL PERIODABATACEPT DURING OPEN-LABEL EXTENSION PERIODABATACEPT DURING LONG-TERM EXTENSION PERIOD
Psoriatic arthropathyMusculoskeletal and connective tissue disorders0/2131/2112/3823/3223/106
OsteoarthritisMusculoskeletal and connective tissue disorders0/2130/2110/3824/3222/106
Abdominal painGastrointestinal disorders0/2130/2110/3820/3221/106
Pancreatitis acuteGastrointestinal disorders0/2130/2110/3820/3221/106
Cholecystitis acuteHepatobiliary disorders0/2131/2111/3821/3221/106
Hepatic fibrosisHepatobiliary disorders0/2130/2110/3820/3221/106
GastroenteritisInfections and infestations2/2130/2110/3820/3221/106
Groin abscessInfections and infestations0/2130/2110/3820/3221/106
Tooth abscessInfections and infestations0/2130/2110/3820/3221/106
Meniscus injuryInjury, poisoning and procedural complications0/2130/2110/3820/3221/106
Most frequent other events
Most frequent other events
EventABATACEPT DURING DOUBLE-BLIND PERIODPLACEBO DURING DOUBLE-BLIND PERIODABATACEPT DURING OPEN-LABEL PERIODABATACEPT DURING OPEN-LABEL EXTENSION PERIODABATACEPT DURING LONG-TERM EXTENSION PERIOD
NasopharyngitisInfections and infestations9/21311/21117/38226/32216/106
BronchitisInfections and infestations7/2135/21119/38217/32215/106
Back painMusculoskeletal and connective tissue disorders4/2132/21110/38211/32212/106
CatarrhRespiratory, thoracic and mediastinal disorders1/2130/2111/3822/32212/106
HypertensionVascular disorders5/2138/21110/3827/3229/106
Urinary tract infectionInfections and infestations10/2132/21110/38212/3228/106
Upper respiratory tract infectionInfections and infestations6/21314/21123/38219/3223/106
PharyngitisInfections and infestations0/2132/2115/38210/3226/106
SciaticaNervous system disorders1/2130/2112/3821/3226/106
InfluenzaInfections and infestations4/2133/2119/38217/3224/106

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)AbataceptPlaceboTotal
Mean51.0 ± 10.6749.8 ± 11.2650.4 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)AbataceptPlaceboTotal
Female121112233
Male9299191
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AbataceptPlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White195198393
More than one race181129
Unknown or Not Reported011
08

Study locations

82 sites
  • Arizona Arthritis & Rheumatology Research PLLC
    Phoenix, Arizona 85037, United States
  • Arthritis Asso & Osteo Ctr Of Colorado Springs
    Colorado Springs, Colorado 80920, United States
  • Joao Nascimento
    Bridgeport, Connecticut 06606, United States
  • New England Research Associates, Llc
    Trumbull, Connecticut 06611, United States
  • Sarasota Arthritis Research Center
    Sarasota, Florida 34239, United States
  • Klein And Associates, M.D., Pa
    Hagerstown, Maryland 21740, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • St. Paul Rheumatology, P.A.
    Eagan, Minnesota 55121, United States
  • Box Arthritis And Rheumatology Of The Carolinas, Pllc
    Charlotte, North Carolina 28210, United States
  • Paramount Medical Research & Consulting, Llc
    Middleburg Heights, Ohio 44130, United States
  • Health Research Of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • East Penn Rheumatology Associates, P.C.
    Bethlehem, Pennsylvania 18015, United States
  • Clinical Research Center Of Reading, Llc
    Wyomissing, Pennsylvania 19610, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Rheumatology Consultants Pllc
    Knoxville, Tennessee 37909-1907, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98122, United States
  • Arthritis Northwest
    Spokane, Washington 99204, United States
  • Local Institution
    Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
  • Instituto de Asistencia Reumatologica Integral
    San Fernando, Buenos Aires 1646, Argentina
  • Caici
    Rosario, Santa FE 2000, Argentina
  • Centro Medico Privado De Reumatologia
    San Miguel De Tucuman, Tucuman 4000, Argentina
  • Instituto De Rehabilitacion Psicofisica
    Buenos Aires, 1428, Argentina
  • Instituto Reumatologico Strusberg
    Cordoba, 5000, Argentina
  • Local Institution
    Juiz De Fora, Minas Gerais 36010-570, Brazil
  • Local Institution
    Curitiba, Parana 80440-080, Brazil
  • Nexus Clinical Research
    St. John's, Newfoundland and Labrador A1A 5E8, Canada
  • Toronto Western Hospital, University Health Network
    Toronto, Ontario M5T 2S8, Canada
  • Manna Research
    Toronto, Ontario M9W 4L6, Canada
  • Groupe De Recherche En Rhumatologie Et Maladies Osseuses
    Quebec, G1V 3M7, Canada
  • Local Institution
    Santiago de Chile, Metropolitana 0, Chile
  • Local Institution
    Vina del Mar, Valparaiso 2520997, Chile
  • Local Institution
    Santiago de Chile, 7500010, Chile
  • Riesgo De Fractura
    Bogota, Cundinamarca, Colombia
  • Servimed E.U
    Bucaramanga, Colombia
  • Clinica de Artritis Temprana
    Cali, Colombia
  • Local Institution
    Praha 11, 148 00, Czechia
  • Local Institution
    Praha 2, 128 50, Czechia
  • Local Institution
    Praha 4, 140 00, Czechia
  • Local Institution
    Chambray Les Tours, 37170, France
  • Local Institution
    Lille Cedex, 59037, France
  • Local Institution
    Montpellier Cedex 5, 34295, France
  • Local Institution
    Poitiers, 86021, France
  • Local Institution
    Strasbourg, 67098, France
  • Local Institution
    Bad Abbach, 93077, Germany
  • Local Institution
    Erlangen, 91054, Germany
  • Local Institution
    Freiburg, 79106, Germany
  • Local Institution
    Hamburg, 22081, Germany
  • Local Institution
    Muenchen, 80336, Germany
  • Local Institution
    Ratingen, 40878, Germany
  • Local Institution
    Trier, 54292, Germany
  • Local Institution
    Athens, 11527, Greece
  • Local Institution
    Crete, 71110, Greece
  • Local Institution
    Ashkelon, 78278, Israel
  • Local Institution
    Haifa, 34362, Israel
  • Local Institution
    Ramat-gan, 52621, Israel
  • Local Institution
    Tel Aviv, 64239, Israel
  • Local Institution
    Firenze, 50139, Italy
  • Local Institution
    Milano, 20122, Italy
  • Local Institution
    Palermo, Italy
  • Local Institution
    Viale Europa Cantanzaro, 88100, Italy
  • Local Institution
    Mexico, Distrito Federal 06090, Mexico
  • Local Institution
    Guadalajara, Jalisco 44650, Mexico
  • Local Institution
    Zapopan, Jalisco 45190, Mexico
  • Local Institution
    Monterrey, N.l., Nuevo Leon 64460, Mexico
  • Local Institution
    Merida, Yucatan 97000, Mexico
  • Local Institution
    Merida, Yucatan 97070, Mexico
  • Local Institution
    Aguascalientes, 20127, Mexico
  • Clinica San Felipe
    Lima, LIMA 11, Peru
  • Hospital Nacional Guillermo Almenara Irigoyen
    Lima, LIMA 13, Peru
  • Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac
    Lima, LIMA 33, Peru
  • Local Institution
    Elblag, Warminsko-mazurski 82-300, Poland
  • Local Institution
    Dabrowka, 62-069, Poland
  • Local Institution
    Myslowice, 41-400, Poland
  • Local Institution
    Warsaw, 01-518, Poland
  • Local Institution
    Pretoria, Gauteng 0002, South Africa
  • Local Institution
    Pretoria, Gauteng 0084, South Africa
  • Local Institution
    Cape Town, Western CAPE 7500, South Africa
  • Local Institution
    Pinelands, Cape Town, Western Cape 7405, South Africa
  • Local Institution
    Stellenbosch, Western Cape 7600, South Africa
  • Local Institution
    A Coruna, 15006, Spain
  • Local Institution
    Santander, 39008, Spain
  • Local Institution
    Sevilla, 41009, Spain
09

References and documents

Publications

  • McInnes IB, Ferraccioli G, D'Agostino MA, Le Bars M, Banerjee S, Ahmad HA, Elbez Y, Mease PJ. Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial. RMD Open. 2019 May 30;5(1):e000934. doi: 10.1136/rmdopen-2019-000934. eCollection 2019. PubMed 31245054 ↗
  • Strand V, Alemao E, Lehman T, Johnsen A, Banerjee S, Ahmad HA, Mease PJ. Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. Arthritis Res Ther. 2018 Dec 6;20(1):269. doi: 10.1186/s13075-018-1769-7. PubMed 30522501 ↗
  • Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4. PubMed 28473423 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Jul 2015, 24 months.

Results were first posted in Aug 2017, 2 years after primary completion. A results delay was requested in Jun 2016.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 24 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2013
First posted
May 23, 2013
StartActual
Jun 17, 2013
Primary completionActual
Jul 14, 2015
CompletionActual
Jun 30, 2020
Results delay requested
Jun 3, 2016
Results first posted
Aug 2, 2017
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01860976
Responsible party
Sponsor
First posted
May 23, 2013
Start date
Jun 17, 2013
Primary completion
Jul 14, 2015
Completion
Jun 30, 2020
Results posted
Aug 2, 2017
Last update
Apr 5, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion